Tag Archives: glucose monitoring

As cancer treatment becomes increasingly sophisticated, clinicians are encountering a growing metabolic challenge. Cancer therapy–induced hyperglycemia has emerged as an important concern with the expanding use of immunotherapies and targeted therapies. In some patients, hyperglycemia develops gradually. In others, particularly those receiving immune checkpoint inhibitors, severe diabetes and diabetic ketoacidosis …

Continuous glucose monitoring (CGM) has transformed diabetes management by giving patients real-time glucose data, trend arrows, and alerts that support better daily decisions. Yet some patients stop using their CGM within days of starting. Often, the problem is not the device itself. Instead, early frustration begins when patients leave the …

Many healthcare providers focus heavily on daytime glucose control, yet some of the most dangerous hypoglycemic episodes occur while patients are asleep. Despite major advances in insulin therapy and glucose monitoring, nocturnal hypoglycemia remains a significant clinical concern for people living with diabetes. Because symptoms often go unnoticed during sleep, …

Many hospitals now treat surgery as more than a single procedure. Increasingly, it has become an opportunity to uncover hidden health conditions that may otherwise go undetected for years. One important trend is perioperative diabetes screening, which helps health systems identify patients with undiagnosed diabetes and prediabetes before surgery begins. …

A bowl of oatmeal can keep one person’s glucose stable while sending another person’s blood sugar sharply upward. The meal is identical, yet the metabolic response is completely different. That reality is pushing many clinicians to reconsider one of the most established principles in diabetes nutrition: carb counting. The growing …

Cancer treatment is evolving rapidly, and with that progress comes a new challenge for clinicians managing glucose disorders. As immune checkpoint inhibitors (ICIs) and PI3K inhibitors become more widely used in oncology, therapy-related hyperglycemia is appearing more often in clinical practice. Many patients receiving cancer treatment now face unexpected glucose …

As GLP-1 therapies become a long-term cornerstone in diabetes care, monitoring patients on these treatments is gaining renewed attention. Clinicians once focused mainly on A1C and weight, but is that enough today? Much like checking only the speed of a car without looking at fuel or engine health, relying on …

Artificial intelligence (AI) is transforming many aspects of diabetes care, and smart insulin management powered by AI is quickly becoming one of its most promising innovations. Tools that read continuous glucose monitor (CGM) data and suggest insulin changes are rapidly entering clinical use. But while these tools are powerful, they …

For decades, clinicians have relied on A1C as the primary benchmark for diabetes control. Yet many patients and providers now wonder: does a single quarterly number truly reflect daily glucose fluctuations and risks? As continuous glucose monitoring (CGM) becomes more accessible, the metric known as Time in Range (TIR) has …